Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Neda Alrawashdh, PharmD, Ali McBride, PharmD, MS, Marion Slack, PhD, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-136358

Published: 2020

Journal Articles

Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model

Ali McBride, PharmD, MS, Daniel O. Persky, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-141748

Published: 2020

Journal Articles

A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy

Trace Bartels, BS, Logan Moore, Neda Alrawashdh, PharmD, Abhijeet Kumar, Ivo Abraham, PhD RN, Daniel O. Persky, MD, Ali McBride, PharmD, MS

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-141651

Published: 2020

Journal Articles

Economic Evaluation of Daratumumab and Pomalidomide and Dexamethasone Versus Isatuximab and Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Neda Alrawashdh, PharmD, Abdulaali Almutairi, Ali McBride, PharmD, MS, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136348

Published: 2020

Journal Articles

Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate

Ali McBride, PharmD, MS, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-142749

Published: 2020

Journal Articles

Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma

Ali McBride, PharmD, MS, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136810

Published: 2020

Journal Articles

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

Leila Jafari, Jubair Hussain, Ravi Krishnadasan, MD, Keri R Maher, DO, Faiz Anwer, MD, Emad Elquza, MD MBA, Christopher Campen, PharmD, Lauren Sanders, PharmD, Alyssa Henglefelt, PharmD, Alicia Ortega, PharmD, Ali McBride, PharmD,MS

Blood (2019) 134 (Supplement_1): 2153.

https://doi.org/10.1182/blood-2019-132121

Published: 2019

Journal Articles

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Logan Moore, Trace Bartels, BS, Daniel O. Persky, MD, Abhijeet Kumar, Ivo Abraham, PhD RN, Lauren Sanders, PharmD, Alicia Ortega, PharmD, Alyssa Henglefelt, PharmD, Ali McBride, PharmD,MS

Blood (2019) 134 (Supplement_1): 5353.

https://doi.org/10.1182/blood-2019-132148

Published: 2019

Journal Articles

Healthcare Resource Utilization with Rasburicase in the Management of Patients with Tumor Lysis in the Outpatient Setting: Results from a Community Oncology Cohort

Ali McBride, PharmD,MS, Melissa Hagan, PhD, Mei Xue, MBA, Robert E Smith, MD

Blood (2019) 134 (Supplement_1): 3401.

https://doi.org/10.1182/blood-2019-125922

Published: 2019

Journal Articles

Elderly AML: A Five-Year Retrospective Review on Prognostic Features

Akshay Amaraneni, MD, Jennifer Segar, MD, Trace Bartels, BS, Onyemaechi Okolo, MD, Andrew C Rettew, DO, Ali McBride, PharmD, MS, Faiz Anwer, MD, Keri R Maher, DO

Blood (2018) 132 (Supplement 1): 5187.

https://doi.org/10.1182/blood-2018-99-111418

Published: 2018

Journal Articles

Recurrent Venous Thromboembolism (VTE), Major Bleeding (MB), and Associated Cost of Treatment with Low Molecular Weight Heparin (LMWH) or Direct Oral Anticoagulant (DOAC) in High Risk Patients with Gastrointestinal (GI) Malignancies: Retrospective Real-World Analysis at a Comprehensive Cancer Center

Alejandro Recio Boiles, MD, Ali McBride, PharmD,MS, Hani M. Babiker, MD, Nimer Alsaid, PhD MS, PharmD, Ivo Abraham, PhD RN, Emad Elquza, MD MBA

Blood (2018) 132 (Supplement 1): 5057.

https://doi.org/10.1182/blood-2018-99-114204

Published: 2018

Journal Articles

Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review

Muhammad Aadil Rahman, MD, Ali Younas Khan, MD, Awais Ijaz, MD, Muhammad Junaid Tariq, MD, Muhammad Usman, MD, Muhammad Jahanzeb Khalil, MD, Muhammad Asad Fraz, MD, Faiza Jamil, MD, Abdul Rafae, MD, Mustafa Nadeem Malik, MD, Insija Ilyas Selene, MBBS, Jemin Aby Jose, MD, Ahmad Safdar, BS, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 2025.

https://doi.org/10.1182/blood-2018-99-115214

Published: 2018

Journal Articles

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

Ali McBride, PharmD, MS, Sanjeev Balu, PhD, Kim Campbell, PharmD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2018-99-113283

Published: 2018

Journal Articles

Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Neda Alrawashdh, Nimer Alkhatib, Ali McBride, PharmD, MS, Daniel Persky, MD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2018-99-112619

Published: 2018

Journal Articles

A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion

Ali McBride, PharmD,MS, Muhammad Usman, MD, Muhammad Jahanzeb Khalil, MD, Muhammad Junaid Tariq, MD, Muhammad Asad Fraz, MD, Awais Ijaz, MD, Malik Qistas Ahmad, MD MBBS, Ali Younas Khan, MD, Sharoon Samuel, MD, Insija Ilyas Selene, MBBS, James Camamo, Cara Chang, PharmD, Jemin Aby Jose, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5667.

https://doi.org/10.1182/blood-2018-99-119736

Published: 2018

Journal Articles

Efficacy and Toxicity Profile of Elotuzumab for Multiple Myeloma: A Systematic Review and Meta-Analysis

Faiza Jamil, MD, Madeeha Shafqat, Sharoon Samuel, MBBS, Zunairah Shah, MBBS, Ceren Durer, MD, Seren Durer, MD, Maryam Sadiq, MBBS, Muhammad Junaid Tariq, MD, Jemin Aby Jose, MD, Warda Faridi, MD, Mohamed Mokhtar Bakr, MD, Umar Zahid, MD, Ali McBride, PharmD, MS, Ahmad Safdar, BS, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5640.

https://doi.org/10.1182/blood-2018-99-117209

Published: 2018

Journal Articles

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Ali McBride, PharmD,MS, Andriy Krendyukov, MD MBA, Nicola Mathieson, Kim Campbell, PharmD, Sanjeev Balu, PhD, Karen MacDonald, PhD, Ivo Abraham, PhD RN

Blood (2018) 132 (Supplement 1): 2251.

https://doi.org/10.1182/blood-2018-99-116315

Published: 2018

Journal Articles

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Ali McBride, PharmD,MS, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham, PhD RN, Sanjeev Balu

Blood (2017) 130 (Supplement 1): 3380.

https://doi.org/10.1182/blood.V130.Suppl_1.3380.3380

Published: 2017

Journal Articles

Using an Enhanced Electronic Heath Record to Analyze Treatment Patterns and Clinical Characteristics in Patients with Relapsed or Refractory Multiple Myeloma Receiving Pomalidomide

Ali McBride, PharmD,MS, Zoe Clancy, MS, PharmD, Jorge Mouro, MS, Marc Tian, PhD MPH, Safiya Abouzaid, MPH, PharmD, Joshua R Richter, MD

Blood (2017) 130 (Supplement 1): 5673.

https://doi.org/10.1182/blood.V130.Suppl_1.5673.5673

Published: 2017

Journal Articles

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Imad Ud Deen, MBBS, Muhammad Umar Khalid, MD, Atlantis Dawn Russ, MD PhD, Anh Hua, BS, Ahmad Iftikhar, MD, Adeela Mushtaq, MD, Ahmad Safdar, BS, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5399.

https://doi.org/10.1182/blood.V130.Suppl_1.5399.5399

Published: 2017

NARROW

Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma - Results of an Evidence-Based Budget Impact Model

A Comparison of Same Day Versus Next Day Administration of Pegfilgrastim in Lymphoma Patients Receiving CHOP Chemotherapy

Economic Evaluation of Daratumumab and Pomalidomide and Dexamethasone Versus Isatuximab and Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate

Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma

Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting

Outcomes of Primary and Secondary Prophylaxis of Chemotherapy Induced and Febrile Neutropenia (CIN/FN) in Bendamustine Plus Rituximab (BR) Regimens in Patients with Lymphoma and Chronic Lymphocytic Leukemia (CLL): Real-World, Single-Center Experience

Healthcare Resource Utilization with Rasburicase in the Management of Patients with Tumor Lysis in the Outpatient Setting: Results from a Community Oncology Cohort

Elderly AML: A Five-Year Retrospective Review on Prognostic Features

Recurrent Venous Thromboembolism (VTE), Major Bleeding (MB), and Associated Cost of Treatment with Low Molecular Weight Heparin (LMWH) or Direct Oral Anticoagulant (DOAC) in High Risk Patients with Gastrointestinal (GI) Malignancies: Retrospective Real-World Analysis at a Comprehensive Cancer Center

Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review

Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: Economic Modeling for the US

Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion

Efficacy and Toxicity Profile of Elotuzumab for Multiple Myeloma: A Systematic Review and Meta-Analysis

Cost Simulation for Febrile Neutropenia Hospitalization in the US Due to Pegfilgrastim on-Body Injector Failure Compared to Single-Injection Pegfilgrastim and Daily Injections with Reference and Biosimilar Filgrastim in Non-Hodgkin Lymphoma

Expanded Access to Obinutuzumab from Cost-Savings Generated By Biosimilar Filgrastim-Sndz in the Prophylaxis of Chemotherapy-Induced (Febrile) Neutropenia: US Simulation Study

Using an Enhanced Electronic Heath Record to Analyze Treatment Patterns and Clinical Characteristics in Patients with Relapsed or Refractory Multiple Myeloma Receiving Pomalidomide

A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only